Study finds rising patent thickets may slow generic drug competition

A recent special communication in JAMA reports that the number of patents linked to FDA‑approved small‑molecule drugs has risen over the past 15 years. The increase is driven largely by non‑primary patents, which are not directly related to the drug's active ingredient.

The authors suggest that this growing web of patents, often called a "patent thicket," could create barriers for generic manufacturers seeking to bring lower‑cost versions to market.

The analysis highlights a potential challenge for competition in the pharmaceutical sector, emphasizing the need for policymakers to consider how patent strategies affect drug pricing and accessibility.

The report does not propose specific regulatory changes but underscores the importance of monitoring patent practices as part of broader efforts to promote affordable medicines.